Sertraline hydrochloride polymorphs

Abstract

The present invention is directed to forms II, III, V, VI, VII, VIII, IX and X of sertraline hydrochloride and novel methods for their preparation. According to the present invention, sertraline hydrochloride polymorph II may be produced by slurrying sertraline hydrochloride polymorph VI in aprotic organic solvent. Sertraline hydrochloride polymorphic form III may be produced by heating sertraline hydrochloride polymorphs V and VI. Sertraline hydrochloride forms V and VI may be produced from either sertraline hydrochloride or sertraline base by crystallization. Sertraline hydrochloride Form VII may be produced by suspending sertraline chloride polymorph V in water, followed by filtration. Sertraline hydrochloride Forms VIII and IX may be produced by suspending sertraline base in water followed by acidification and filtration. Sertraline hydrochloride Form X may be produced by suspending sertraline hydrochloride in benzyl alcohol with heating, followed by filtration.

What is claimed is:  
     
         1 . A process for making sertraline hydrochloride Form V comprising the steps of: 
 (a) dissolving sertraline hydrochloride in a suitable solvent;    (b) removing the solvent; and    (c) drying to form sertraline hydrochloride Form V.    
     
     
         2 . The process of  claim 1 , wherein the solvent is selected from the group consisting of methanol, ethanol, water, methoxypropanol, and, isopropyl alcohol and mixtures thereof.  
     
     
         3 . The process of  claim 2  wherein the solvent is methanol.  
     
     
         4 . The process of  claim 2  wherein the solvent is ethanol.  
     
     
         5 . The process of  claim 2  wherein the solvent is a mixture of isopropyl alcohol and water.  
     
     
         6 . The process of  claim 1 , further comprising the steps of seeding the solution with sertraline hydrochloride Form V.  
     
     
         7 . The process of  claim 1  wherein the sertraline hydrochloride of step (a) is sertraline hydrochloride Form I.  
     
     
         8 . The process of  claim 1  wherein the sertraline hydrochloride of step (a) is sertraline hydrochloride Form VI.  
     
     
         9 . The process of  claim 1  wherein the sertraline hydrochloride of step (a) is sertraline hydrochloride Form VII.  
     
     
         10 . The process of  claim 1  wherein the sertraline hydrochloride of step (a) is sertraline hydrochloride Form VIII.  
     
     
         11 . The process of  claim 1  wherein the sertraline hydrochloride of step (a) is sertraline hydrochloride Form IX.  
     
     
         12 . A process for making sertraline hydrochloride Form V comprising the steps of: 
 (a) dissolving or suspending sertraline base in a solvent,    (b) adding hydrogen chloride or hydrochloric acid to reduce the pH of the solution or suspension; and    (c) isolating sertraline hydrochloride Form V.    
     
     
         13 . The process of  claim 12  wherein the pH of the solution or suspension of sertraline base and hydrogen chloride of hydrochloric acid is a solvent is about 0 to about 4.  
     
     
         14 . The process of  claim 12  wherein the solvent is selected from the group consisting of methanol, ethanol, water, ethyl acetate, isopropyl alcohol, hexane, and toluene and mixtures thereof.  
     
     
         15 . The process of  claim 14  wherein the solvent is methanol.  
     
     
         16 . The process of  claim 14  wherein the solvent is ethanol.  
     
     
         17 . The process of  claim 14  wherein the solvent is water.  
     
     
         18 . The process of  claim 14  wherein the solvent is a mixture of hexane and isopropyl alcohol.  
     
     
         19 . The process of  claim 14  wherein the solvent is a mixture of isopropyl alcohol and water.  
     
     
         20 . The process of  claim 14  wherein the solvent is a mixture of ethanol and water.  
     
     
         21 . The process of  claim 14  wherein the solvent is ethyl acetate.  
     
     
         22 . The process of  claim 14  wherein the solvent is a mixture of ethanol and isopropyl alcohol.  
     
     
         23 . The process of  claim 14  wherein the solvent is a mixture of methanol and isopropyl alcohol.  
     
     
         24 . A pharmaceutical composition comprising a therapeutically effective amount of sertraline hydrochloride Form V and a pharmaceutically acceptable carrier.  
     
     
         25 . A process for making sertraline hydrochloride Form V comprising the step of drying sertraline hydrochloride ethanolate Form VI.  
     
     
         26 . A process for making sertraline hydrochloride Form V comprising the step of drying sertraline hydrochloride Form VII.  
     
     
         27 . A process for making sertraline hydrochloride Form V comprising the step of drying sertraline hydrochloride hydrate Form VIII.  
     
     
         28 . A process for making sertraline hydrochloride Form V comprising the steps of: 
 (a) suspending or dissolving sertraline hydrochloride in a solvent selected form the group consisting of ethanol, methanol and water and mixtures thereof; and    (b) isolating sertraline hydrochloride Form V.    
     
     
         29 . A process for making sertraline hydrochloride Form V comprising the steps of: 
 (a) dissolving sertraline hydrochloride Form VI in water;    (b) adding a sufficient amount of hydrochloric acid or hydrogen chloride to facilitate precipitation of sertraline hydrochloride Form V;    (c) removing the water; and    (d) isolating sertraline hydrochloride Form V.    
     
     
         30 . A process for making sertraline hydrochloride Form V comprising the steps of: 
 (a) heating amorphous sertraline hydrochloride for a time sufficient to effect the transformation to sertraline hydrochloride Form V; and    (b) isolating sertraline hydrochloride Form V.    
     
     
         31 . The process of  claim 30  wherein amorphous sertraline hydrochloride is heated to a temperature up to about 80° C.  
     
     
         32 . Sertraline hydrochloride Form VI.  
     
     
         33 . Sertraline hydrochloride Form VI ethanolate.  
     
     
         34 . Sertraline hydrochloride Form VI methanolate.  
     
     
         35 . Sertraline hydrochloride Form VI, which is characterized by an x-ray powder diffraction pattern comprising peaks at about 7.3°±0.2, 12.1°±0.2, 12.7°±0.2, 22.0°±0.2, 22.9°±0.2, 23.2°±0.2, 24.0°±0.2, and 24.5°±0.2 degrees two-theta.  
     
     
         36 . A pharmaceutical composition comprising a therapeutically effective amount of sertraline hydrochloride Form VI and a pharmaceutically acceptable carrier.  
     
     
         37 . A process for making sertraline hydrochloride Form VI comprising the steps of: 
 (a) dissolving sertraline base in a solvent;    (b) adding hydrogen chloride gas to the solution; and    (c) isolating sertraline hydrochloride Form VI without further drying.    
     
     
         38 . The process of  claim 37  wherein the isolation step comprises precipitation of sertraline hydrochloride Form VI followed by filtration.  
     
     
         39 . The process of  claim 37  wherein the solvent is ethanol or methanol.  
     
     
         40 . The product of the process of  claim 37 .  
     
     
         41 . A process for making sertraline hydrochloride Form VI comprising the steps of: 
 (a) dissolving sertraline hydrochloride in ethanol or methanol;    (b) stirring for a time sufficient to induce the transformation of sertraline hydrochloride to sertraline hydrochloride Form VI; and    (c) isolating sertraline hydrochloride Form VI.    
     
     
         42 . The process of  claim 41  wherein the sertraline hydrochloride of step (a) is Form I.  
     
     
         43 . The process of  claim 41  wherein the sertraline hydrochloride of step (a) is Form II.  
     
     
         44 . The process of  claim 41  wherein the sertraline hydrochloride of step (a) is Form V.  
     
     
         45 . Sertraline hydrochloride Form VII.  
     
     
         46 . A pharmaceutical composition comprising a therapeutically effective amount of sertraline hydrochloride Form VII, and a pharmaceutically acceptable carrier.  
     
     
         47 . A process for making sertraline hydrochloride Form VII comprising the steps of: 
 (a) suspending sertraline hydrochloride Form V in water; and    (b) filtering the suspension without drying.    
     
     
         48 . The product of the process of  claim 47 .  
     
     
         49 . A process for making sertraline hydrochloride Form VII comprising the steps of: 
 (a) dissolving sertraline hydrochloride ethanolate Form VI in water such that the sertraline hydrochloride Form VI is converted to sertraline hydrochloride Form VII;    (b) filtering the sertraline hydrochloride Form VII; and    (c) washing the filtered sertraline hydrochloride Form VII with water.    
     
     
         50 . A process for making sertraline hydrochloride Form VII comprising the steps of: 
 (a) dissolving sertraline hydrochloride ethanolate Form VI in water;    (b) heating the solution to facilitate dissolution of sertraline hydrochloride Form VI; and    (c) isolating sertraline hydrochloride Form VII without drying.    
     
     
         51 . The process of  claim 50  comprising the additional step of lowering the pH to facilitate precipitation of sertraline hydrochloride Form V.  
     
     
         52 . Sertraline hydrochloride Form VII, which is characterized by the x-ray powder diffraction pattern substantially depicted in FIG. 6.  
     
     
         53 . Sertraline hydrochloride hydrate Form VIII.  
     
     
         54 . Sertraline hydrochloride Form VIII, which is characterized by an x-ray powder diffraction pattern comprising peaks at about 4.7°±0.2, 16.3°±0.2, 17.8°±0.2, 19.6°±0.2, 23.2°±0.2, 24.2°±0.2, 25.1°±0.2, and 26.0°±0.2 two-theta.  
     
     
         55 . A pharmaceutical composition comprising a therapeutically effective amount of sertraline hydrochloride Form VIII, and a pharmaceutically acceptable carrier.  
     
     
         56 . A process for making sertraline hydrochloride Form VIII comprising the steps of: 
 (a) suspending sertraline base in water;    (b) adding hydrochloric acid; and    (c) filtrating the precipitate so obtained without further drying.    
     
     
         57 . The product of the process of  claim 58 .  
     
     
         58 . A process for making sertraline hydrochloride Form VIII comprising the steps of: 
 (a) dissolving sertraline hydrochloride ethanolate Form VI in water; and    (b) isolating sertraline hydrochloride Form VIII.    
     
     
         59 . A process for making sertraline hydrochloride Form VIII comprising the steps of: 
 (a) dissolving sertraline hydrochloride Form II in water; and    (b) isolating sertraline hydrochloride Form VIII.    
     
     
         60 . Sertraline hydrochloride Form IX which is characterized by the x-ray diffraction pattern substantially as depicted in FIG. 8.  
     
     
         61 . Sertraline hydrochloride Form IX, which is characterized by an x-ray powder diffraction pattern comprising peaks at about 5.1°±0.2, 14.2°±0.2, 15.8°±2.0, 16.8°±0.2, 19.2°±0.2, 19.7°±2.0, 22.4°±2.0, 23.2°±0.2, 25.3°±0.2 and 26.1°±0.2 two-theta.  
     
     
         62 . A pharmaceutical composition comprising a therapeutically effective amount of sertraline hydrochloride Form IX, and a pharmaceutically acceptable carrier.  
     
     
         63 . A process for making sertraline hydrochloride Form IX comprising the steps of: 
 (a) suspending sertraline base in water;    (b) adding hydrochloric acid such that a precipitate is formed;    (c) filtrating the precipitate; and    (d) drying the precipitate.    
     
     
         64 . The product of the process of  claim 63 .  
     
     
         65 . A process for making sertraline hydrochloride Form IX comprising the step of drying sertraline hydrochloride Form VIII and isolating sertraline hydrochloride Form IX.  
     
     
         66 . A process for making sertraline hydrochloride Form X comprising the steps of: 
 (a) suspending sertraline hydrochloride in benzyl alcohol;    (b) heating the suspension to facilitate dissolution;    (c) cooling the solution such that a precipitate is formed;    (d) heating the solution to about 80° C.; and    (e) isolating sertraline hydrochloride Form X.    
     
     
         67 . The process of  claim 66  wherein the sertraline hydrochloride Form X is isolated by filtration and washing with benzyl alcohol and heating.  
     
     
         68 . The product of the process of  claim 66 .  
     
     
         69 . Sertraline hydrochloride Form X.  
     
     
         70 . Sertraline hydrochloride Form X which is characterized by an x-ray powder diffraction pattern comprising peaks at about 15.0°±0.2, 16.0°±0.2, 16.5°±0.2, 17.0°±0.2, 18.1°±0.2, 21.0°±0.2, 22.4°±0.2, 24.9°±0.2, 25.4°±0.2, 26.2°±0.2, 27.1°±0.2, 28.4°±0.2, and 29.0°±0.2 degrees two-theta.  
     
     
         71 . A pharmaceutical composition comprising a therapeutically effective amount of sertraline hydrochloride Form X, and a pharmaceutically acceptable carrier.  
     
     
         72 . A process for making sertraline hydrochloride Form II comprising the steps of: 
 (a) suspending sertraline hydrochloride Form VI in an organic aprotic solvent for a time sufficient to effect transformation to Form II; and    (b) filtrating the suspension.    
     
     
         73 . The process of  claim 72  wherein the process takes place at temperature between about 25° C. and about 80° C.  
     
     
         74 . The process of  claim 72  in which the sertraline hydrochloride form VI is suspended in about 1 to about 10 volumes of organic aprotic solvent.  
     
     
         75 . The process of  claim 72  wherein the solvent is selected from the group consisting of acetone, t-butyl-methyl-ether, cyclohexane, and ethyl acetate.  
     
     
         76 . The process of  claim 77  wherein the solvent is t-butyl-methyl-ether.  
     
     
         77 . The process of  claim 77  wherein the solvent is acetone.  
     
     
         78 . A process for making sertraline hydrochloride Form II comprising the steps of: 
 (a) suspending sertraline hydrochloride Form V in dimethylformamide or cyclohexanol;    (b) heating the solution for a time sufficient to effect transformation to sertraline hydrochloride Form II; and    (c) isolating sertraline hydrochloride Form II.    
     
     
         79 . A process for making sertraline hydrochloride Form II comprising the steps of: 
 (a) dissolving sertraline base in acetone;    (b) adding a hydrogen chloride solution to induce the formation of sertraline hydrochloride Form II; and    (c) isolating sertraline hydrochloride Form II.    
     
     
         80 . A process for making sertraline hydrochloride Form II comprising the steps of: 
 (a) granulating sertraline hydrochloride Form V with ethanol; and    (b) stirring the mixture for a time sufficient to induce transformation to sertraline hydrochloride Form II.    
     
     
         81 . A process for making a mixture of sertraline hydrochloride Form II and Form V comprising the steps of: 
 (a) heating sertraline hydrochloride ethanolate Form VI at up to 1 atmosphere pressure; and    (b) isolating a mixture of sertraline hydrochloride Form II and Form V.    
     
     
         82 . The process of  claim 81  wherein the sertraline hydrochloride Form VI is heated to about 80° C. to about 105° C.  
     
     
         83 . A process for making sertraline hydrochloride Form III comprising the steps of: 
 (a) heating sertraline hydrochloride Form V for a time sufficient to induce the transformation of sertraline hydrochloride Form II to sertraline hydrochloride Form V; and    (b) isolating sertraline hydrochloride Form III.    
     
     
         84 . The process of  claim 83  wherein sertraline hydrochloride Form V is heated to about 150° C. to about 180° C.  
     
     
         85 . A process for making sertraline hydrochloride Form III comprising the steps of: 
 (a) heating sertraline hydrochloride Form VI for a time sufficient to induce the transformation of sertraline hydrochloride Form V to sertraline hydrochloride Form III; and    (b) isolating sertraline hydrochloride Form III.    
     
     
         86 . The process of  claim 85  wherein sertraline hydrochloride is heated to about 180° C.  
     
     
         87 . A process for making amorphous sertraline hydrochloride comprising the steps of: 
 (a) suspending or dissolving sertraline base in a non-polar organic solvent;    (b) adding gaseous hydrochloric acid; and    (c) and isolating amorphous sertraline hydrochloride.    
     
     
         88 . The process of  claim 87  wherein the solvent is selected from the group consisting of ether, toluene and t-butyl-methyl ether.  
     
     
         89 . A process for making amorphous sertraline hydrochloride comprising the steps of: 
 (a) lyophilization of sertraline hydrochloride; and    (b) isolating amorphous sertraline hydrochloride.    
     
     
         90 . Amorphous sertraline hydrochloride, which is characterized by the x-ray diffraction pattern substantially as depicted in FIG. 2.